What could a tree possibly reveal about the European Society for Medical Oncology (ESMO)? Quite a lot, says Prof Andres Cervantes, Professor of Medicine at the University of Valencia, Spain ...

Regeneron Pharmaceuticals’ investigational melanoma combination therapy shows continued response after two years in a Phase I ...

Expects to deliver three Investigational New Drug (IND) applications in next three years based on next-generation ADC technology -- Two new ...

Susanne Bobadilla from VML Health, joined by a team of 15 medical, digital strategists and client engagement experts from across the company, looks at the top trends coming out of ESMO 2024 and what ...

A team of researchers have applied a novel blood test that can detect early signs of potentially fatal lung damage in cancer ...

(esmo), a leading global full-service systems integrator, developer, and supplier of innovative and advanced automation ...

Investigators assessed whether intravesical BCG is necessary for patients with high-grade T1 nonmuscle-invasive bladder cancer who have unremarkable histology on the second transurethral resection.

Good morning and welcome to Agenus' third quarter 2024 conference call and webcast. All participants will be in a listen-only ...

Perioperative durvalumab has “the potential to transform the standard of care” for patients with muscle-invasive bladder ...

Merus’ zenocutuzumab is nearing FDA approval, and petosemtamab shows promise. Learn why MRUS stock could rise as the company ...

Shares of Sutro Biopharma (NASDAQ:STRO) fell by 17% in September after the company's ESMO (European Society for Medical Oncology) update. 3-year performance isn't looking much better at -81% ...

EMA granted clearance to advancebelrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in ...